Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Xencor, Inc.
ISIN US98401F1057
|WKN A1W96L
Market cap (in EUR)
1,772 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Pasadena, CA.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 1,772 m |
| EPS, EUR | -1.86 |
| P/B ratio | 4.3 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 111 m |
| Net income, EUR | -81 m |
| Profit margin | -73.20% |
What ETF is Xencor, Inc. in?
There are 32 ETFs which contain Xencor, Inc.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Xencor, Inc. is the L&G Pharma Breakthrough UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.